Alnylam Pharmaceuticals Inc. (ALNY) announced positive results from its Phase I study of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia. ALN-PCS is a PCSK9 synthesis inhibitor that reduces intracellular and extracellular levels of PCSK9 resulting in lowered plasma levels of low-density lipoprotein cholesterol or LDL-C , or "bad" cholesterol.
The trial results demonstrated that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, lead to statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%. Also, the new data highlight continued improved efficacy and tolerability for Alnylam's second-generation lipid nanoparticle or LNP delivery technology.
Phase I study's primary objective was to evaluate the safety and tolerability of a single dose of ALN-PCS, while the secondary objectives included assessment of pharmacodynamic effects of the drug on plasma PCSK9 protein levels and evaluation of clinical efficacy as measured by LDL-C levels.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.